(Q39664633)

13 September 2017

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells (English)

1 reference

13 September 2017

hepatocellular carcinoma

1 reference

1 reference

8

1 reference

13 September 2017

K-F Chen

1

1 reference

13 September 2017

C-Y Liu

2

1 reference

13 September 2017

Y-C Lin

3

1 reference

13 September 2017

H-C Yu

4

1 reference

13 September 2017

T-H Liu

5

1 reference

13 September 2017

D-R Hou

6

1 reference

13 September 2017

P-J Chen

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

23 August 2010

1 reference

13 September 2017

1 reference

13 September 2017

29

1 reference

13 September 2017

47

1 reference

13 September 2017

6257-6266

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.357

13 September 2017

0 references

cites work

Functional analysis of the PP2A subfamily of protein phosphatases in regulating Drosophila S6 kinase

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

CIP2A is associated with human breast cancer aggressivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

CIP2A inhibits PP2A in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Mechanisms of proteasome inhibitor action and resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

PP2A: unveiling a reluctant tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

NF-kappaB as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Proteasome inhibitors in cancer therapy: lessons from the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

The proteasome and proteasome inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.357

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.357

1 reference

13 September 2017

1 reference